Amgen, Sandoz Battle Over High Court's Biosimilar Ruling
In the aftermath of the U.S. Supreme Court's landmark biosimilars ruling, Amgen Inc. and Sandoz Inc. clashed late Monday over whether biosimilar makers can be punished for not divulging their approval...To view the full article, register now.
Already a subscriber? Click here to view full article